Surmodics, Inc. (NASDAQ:SRDX – Get Free Report) saw a large decline in short interest in February. As of February 28th, there was short interest totalling 271,300 shares, a decline of 37.0% from the February 13th total of 430,900 shares. Based on an average daily trading volume, of 271,700 shares, the days-to-cover ratio is currently 1.0 days. Currently, 2.0% of the shares of the stock are short sold.
Surmodics Price Performance
Shares of NASDAQ SRDX traded down $0.02 during trading on Friday, hitting $28.30. The company had a trading volume of 103,729 shares, compared to its average volume of 170,620. The company has a market cap of $404.58 million, a P/E ratio of -28.02 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45. The business’s 50-day moving average is $34.37 and its 200 day moving average is $37.40. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44.
Surmodics (NASDAQ:SRDX – Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. Equities research analysts predict that Surmodics will post 0.2 earnings per share for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Stock Report on SRDX
Institutional Investors Weigh In On Surmodics
Hedge funds have recently made changes to their positions in the company. Modus Advisors LLC purchased a new position in Surmodics during the 4th quarter worth approximately $40,000. Quest Partners LLC grew its holdings in shares of Surmodics by 107,100.0% during the third quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after buying an additional 1,071 shares in the last quarter. R Squared Ltd acquired a new position in Surmodics during the fourth quarter valued at $55,000. Longfellow Investment Management Co. LLC purchased a new stake in Surmodics in the 3rd quarter worth about $67,000. Finally, Legal & General Group Plc boosted its position in Surmodics by 34.2% during the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock worth $137,000 after acquiring an additional 880 shares during the period. Hedge funds and other institutional investors own 96.63% of the company’s stock.
About Surmodics
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Featured Stories
- Five stocks we like better than Surmodics
- The 3 Best Retail Stocks to Shop for in August
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is the Australian Securities Exchange (ASX)
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- What is the Dogs of the Dow Strategy? Overview and Examples
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.